Janssen:Janssen - European Commission Has Granted Marketing Authorisation For Expanded Use Of Darzalex Subcutaneous Formulation In Two New Indications.Janssen - Darzalex Sc Formulation Becomes First Approved Treatment For Newly Diagnosed Systemic Light Chain Amyloidosis In Europe.Janssen - Darzalex Sc Formulation Gains An Additional Approval In Pre-Treated Multiple Myeloma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments